Comparative Pharmacology
Head-to-head clinical analysis: ERYC SPRINKLES versus ILOSONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYC SPRINKLES versus ILOSONE.
ERYC SPRINKLES vs ILOSONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking the translocation of peptidyl-tRNA. It may also act as a motilin receptor agonist, enhancing gastrointestinal motility.
Erythromycin (ILOSONE) binds to the 50S subunit of bacterial ribosomes, inhibiting peptide chain elongation and protein synthesis by blocking translocation.
250-500 mg orally every 6 hours (or 333 mg every 8 hours) for adults; maximum 4 g/day.
Erythromycin (Ilosone) base or stearate: 250-500 mg orally every 6 hours. Estolate: 250-500 mg orally every 6 hours. Maximum dose 4 g/day.
None Documented
None Documented
1.5-2.0 hours in adults with normal renal function; prolonged in neonates (2-4 hours) and patients with hepatic impairment.
1.5-2 hours in adults; prolonged in hepatic impairment (up to 5-6 hours)
Primarily biliary (fecal) elimination (60-80% as unchanged drug) with approximately 5-15% renal excretion of active drug.
Renal (2-5% unchanged), biliary/fecal (majority, >90% as metabolites and unchanged drug)
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic